Cargando…
Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
Oncogenic mutations in BRAF are common in melanoma and thyroid carcinoma and drive constitutive activation of the MAPK pathway. Molecularly targeted therapies of this pathway improves survival compared to chemotherapy; however, responses tend to be short-lived as resistance invariably occursCell lin...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910922/ https://www.ncbi.nlm.nih.gov/pubmed/26828826 http://dx.doi.org/10.1080/15384047.2016.1139230 |
_version_ | 1782438056454782976 |
---|---|
author | Dorris, Emma R. Blackshields, Gordon Sommerville, Gary Alhashemi, Mohsen Dias, Andrew McEneaney, Victoria Smyth, Paul O'Leary, John J. Sheils, Orla |
author_facet | Dorris, Emma R. Blackshields, Gordon Sommerville, Gary Alhashemi, Mohsen Dias, Andrew McEneaney, Victoria Smyth, Paul O'Leary, John J. Sheils, Orla |
author_sort | Dorris, Emma R. |
collection | PubMed |
description | Oncogenic mutations in BRAF are common in melanoma and thyroid carcinoma and drive constitutive activation of the MAPK pathway. Molecularly targeted therapies of this pathway improves survival compared to chemotherapy; however, responses tend to be short-lived as resistance invariably occursCell line models of melanoma and thyroid carcinoma, +/− BRAF(V600E) activating mutation, were treated with the MEK inhibitor PD0325901. Treated and naive samples were assayed for expression of key members of the MAPK pathway. Global microRNA expression profiling of naive and resistant cells was performed via next generation sequencingand indicated pluripotency pathways in resistance. Parental cell lines were progressed to holoclones to confirm the miRNA stemness profileMembers of the MIR302/373/374/520 family of embryonic stem cell specific cell cycle regulating (ESCC) microRNAs were identified as differentially expressed between resistant BRAF(V600E) melanoma and thyroid cell lines. Upregulated expression of gene and protein stemness markers, upregulated expression of MAPK pathway genes and downregulation of the ESCC MIR302 cluster in BRAF(V600E) melanoma indicated an increased stem-like phenotype in resistant BRAF(V600E) melanoma. Conversely, downregulated expression of gene and protein stemness markers, downregulated expression of MAPK pathway genes, upregulation of the ESCC MIR520 cluster, reeexpression of cell surface receptors, and induced differentiation-associated morphology in resistant BRAF(V600E) indicate a differentiated phenotype associated with MEK inhibitor resistance in BRAF(V600E) thyroid cellsThe differential patterns of resistance observed between BRAF(V600E) melanoma and thyroid cell lines may reflect tissue type or de novo differentiation, but could have significant impact on the response of primary and metastatic cells to MEK inhibitor treatment. This study provides a basis for the investigation of the cellular differentiation/self-renewal access and its role in resistance to MEK inhibition. |
format | Online Article Text |
id | pubmed-4910922 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-49109222016-06-29 Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines Dorris, Emma R. Blackshields, Gordon Sommerville, Gary Alhashemi, Mohsen Dias, Andrew McEneaney, Victoria Smyth, Paul O'Leary, John J. Sheils, Orla Cancer Biol Ther Research Paper Oncogenic mutations in BRAF are common in melanoma and thyroid carcinoma and drive constitutive activation of the MAPK pathway. Molecularly targeted therapies of this pathway improves survival compared to chemotherapy; however, responses tend to be short-lived as resistance invariably occursCell line models of melanoma and thyroid carcinoma, +/− BRAF(V600E) activating mutation, were treated with the MEK inhibitor PD0325901. Treated and naive samples were assayed for expression of key members of the MAPK pathway. Global microRNA expression profiling of naive and resistant cells was performed via next generation sequencingand indicated pluripotency pathways in resistance. Parental cell lines were progressed to holoclones to confirm the miRNA stemness profileMembers of the MIR302/373/374/520 family of embryonic stem cell specific cell cycle regulating (ESCC) microRNAs were identified as differentially expressed between resistant BRAF(V600E) melanoma and thyroid cell lines. Upregulated expression of gene and protein stemness markers, upregulated expression of MAPK pathway genes and downregulation of the ESCC MIR302 cluster in BRAF(V600E) melanoma indicated an increased stem-like phenotype in resistant BRAF(V600E) melanoma. Conversely, downregulated expression of gene and protein stemness markers, downregulated expression of MAPK pathway genes, upregulation of the ESCC MIR520 cluster, reeexpression of cell surface receptors, and induced differentiation-associated morphology in resistant BRAF(V600E) indicate a differentiated phenotype associated with MEK inhibitor resistance in BRAF(V600E) thyroid cellsThe differential patterns of resistance observed between BRAF(V600E) melanoma and thyroid cell lines may reflect tissue type or de novo differentiation, but could have significant impact on the response of primary and metastatic cells to MEK inhibitor treatment. This study provides a basis for the investigation of the cellular differentiation/self-renewal access and its role in resistance to MEK inhibition. Taylor & Francis 2016-02-01 /pmc/articles/PMC4910922/ /pubmed/26828826 http://dx.doi.org/10.1080/15384047.2016.1139230 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | Research Paper Dorris, Emma R. Blackshields, Gordon Sommerville, Gary Alhashemi, Mohsen Dias, Andrew McEneaney, Victoria Smyth, Paul O'Leary, John J. Sheils, Orla Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines |
title | Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines |
title_full | Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines |
title_fullStr | Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines |
title_full_unstemmed | Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines |
title_short | Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines |
title_sort | pluripotency markers are differentially induced by mek inhibition in thyroid and melanoma brafv600e cell lines |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910922/ https://www.ncbi.nlm.nih.gov/pubmed/26828826 http://dx.doi.org/10.1080/15384047.2016.1139230 |
work_keys_str_mv | AT dorrisemmar pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines AT blackshieldsgordon pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines AT sommervillegary pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines AT alhashemimohsen pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines AT diasandrew pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines AT mceneaneyvictoria pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines AT smythpaul pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines AT olearyjohnj pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines AT sheilsorla pluripotencymarkersaredifferentiallyinducedbymekinhibitioninthyroidandmelanomabrafv600ecelllines |